Cerity Partners LLC increased its position in Illumina by 23.0% during the third quarter, acquiring an additional 23,417 shares to bring its total holdings to 125,387 shares. This stake represents 0.08% of Illumina’s outstanding stock and was valued at approximately $11.9 million as of the latest SEC 13F filing. The addition underscores Cerity’s continued confidence in Illumina’s core sequencing and array-based platforms.

Other institutional investors have also been active in Illumina. Parkside Financial Bank & Trust raised its stake by 65.7% in the second quarter, adding 115 shares to hold 290 shares. Cullen Frost Bankers initiated a new position valued at roughly $41,000, while NewSquare Capital expanded its stake by 604.9%, acquiring 369 shares to reach 430 shares. In the third quarter, Mather Group purchased a new position worth about $46,000 and SJS Investment Consulting increased its holdings by 13,225%, adding 529 shares to hold 533 shares. Overall, hedge funds and institutional investors now control 89.42% of the company’s shares.

Illumina reported third-quarter earnings per share of $1.34, surpassing consensus estimates by $0.18, on revenue of $1.08 billion, beating forecasts by $10 million. The company delivered a net margin of 16.40% and a return on equity of 29.21%, with revenue up 0.4% year-over-year. Illumina reaffirmed its full-year 2025 EPS guidance range of 4.650 to 4.750, compared to analysts’ average projection of 4.51, signaling continued confidence in growth across its next-generation sequencing and consumables business.

Director Scott Gottlieb added 500 shares in early November, increasing his holdings by 4.16% to 12,523 shares, while executive Scott M. Davies sold 323 shares in mid-December, trimming his position by 1.77% to 17,887 shares. Insiders collectively hold 2.60% of the company. On the analyst front, JPMorgan upgraded its target to support a neutral stance, Canaccord raised its target while maintaining a hold rating, and Barclays nudged down its weight assessment despite a higher price objective. Overall, five analysts rate Illumina as a buy, fourteen as a hold and two as a sell, resulting in a consensus hold rating with an average target near $122.56.